To address this, we assessed the in vitro IL-22 response of allergen-specific CLA+ memory T cells from adults with moderate-to-severe AD, aiming to better define the role of IL-22 in AD and identify patient populations who may potentially benefit from IL-22–targeted therapies. This evidence concerns the gene SELPLG and Alzheimer disease.